特发性醛固酮增多症的治疗进展

Recent progress in the treatment of idiopathic aldosteronism

特发性醛固酮增多症是醛固酮增多症的常见病因。目前治疗首选以螺内酯为主的药物治疗；当药物无法控制血压或患者无法耐受不良反应时，可选择联合其他降压药物或手术治疗改善患者症状。近期该病治疗手段进展迅速，多种螺内酯替代药物包括醛固酮合酶抑制剂、依普利酮等相继出现。本文就目前特发性醛固酮增多症治疗进展做一综述。

The bilateral idiopathic aldosteronism （IHA） is the most common subtype of aldosteronism. Spironolactone is the primary preferred agent due to the pathophysiology of IHA and the long-standing clinical experience over years. If patients faced with severe side effects of spironolactone or poorly controlled blood pressure by this first-line treatment, additional treatment alternative to spironolactone, second antihypertensive, as well as adrenalectomy are suggested. In recent years, several new agents were developed to treat IHA, such as aldosterone synthase inhibitor and eplerenone. This review introduces these new kinds of medicine in the treatment of IHA.